Stefan Križanac
Research Subjects
Research Interests
Stefan Križanac has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Boško Skorić
University Hospital Centre Zagreb (UHC Zagreb)
2 shared publications - Daniel Lovrić
Department of Cardiovascular Diseases, University Hospital Centre Zagreb, 10000 Zagreb, Croatia
2 shared publications - Davor Miličić
University of Zagreb School of Medicine Department of Cardiovascular Diseases, University Hospital Centre Zagreb Zagreb
2 shared publications - Hrvoje Jurin
Department of Cardiovascular Diseases, University Hospital Centre Zagreb, 10000 Zagreb, Croatia
2 shared publications - Marijan Pašalić
Department of Cardiovascular Diseases, University Hospital Centre Zagreb, 10000 Zagreb, Croatia
2 shared publications - Dora Fabijanović
Department of Biology, School of Medicine, University of Zagreb, Zagreb, Croatia
1 shared publication
Latest Publications
- 11 September 2023
- Published by Wiley in Therapeutic Apheresis and Dialysis
- Vol. 28 (1) , 103-111
The addition of Cytosorb in patients on VA‐ECMO improves urinary output and ICU survival
Introduction: The aim of this study was to analyze the efficiency of CytoSorb adsorber in patients presenting with cardiogenic shock and treated with venoarterial extracorporeal membrane oxygenation (VA‐ECMO).Methods: Sixteen patients put on VA ECMO due to cardiogenic shock were included, stratified according to the use of Cytosorb adsorber in the first 24 h and compared across different clinical outcomes.Results: Significantly lower vasopressor doses were required among patients treated with Cytosorb at the initiation and before weaning from ECMO. Furthermore, these patients showed significantly higher urine output before weaning and lower lactate levels during the extracorporeal support. Finally, the mortality rate was lower among the Cytosorb therapy group (22.2% vs 57.1%).Conclusion: While a decrease in vasopressor doses was already associated with CytoSorb use, this is the first study showing an increase in urinary output and a trend towards better survival among patients on VA ECMO treated with CytoSorb.
- 11 September 2023
- Published by Wiley in Therapeutic Apheresis and Dialysis
- Vol. 28 (1) , 103-111
The addition of Cytosorb in patients on VA‐ECMO improves urinary output and ICU survival
Introduction: The aim of this study was to analyze the efficiency of CytoSorb adsorber in patients presenting with cardiogenic shock and treated with venoarterial extracorporeal membrane oxygenation (VA‐ECMO).Methods: Sixteen patients put on VA ECMO due to cardiogenic shock were included, stratified according to the use of Cytosorb adsorber in the first 24 h and compared across different clinical outcomes.Results: Significantly lower vasopressor doses were required among patients treated with Cytosorb at the initiation and before weaning from ECMO. Furthermore, these patients showed significantly higher urine output before weaning and lower lactate levels during the extracorporeal support. Finally, the mortality rate was lower among the Cytosorb therapy group (22.2% vs 57.1%).Conclusion: While a decrease in vasopressor doses was already associated with CytoSorb use, this is the first study showing an increase in urinary output and a trend towards better survival among patients on VA ECMO treated with CytoSorb.
- 1 November 2018
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 13 (11-12) , 455
Predictors of intrahospital mortality of patients older than 80 years hospitalized in a modern intensive cardiac care unit
- 1 November 2018
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 13 (11-12) , 455
Predictors of intrahospital mortality of patients older than 80 years hospitalized in a modern intensive cardiac care unit